Decipher Complement Pathway Intricacies, Validate Pathway Activation Assays & Discover Next-Generation Complement-Targeted Approaches that are Transforming Patient Outcomes

Expert Speakers Include:

- **Madhumita Das**
  Director, Immunology Discovery
  Apellis Pharmaceuticals

- **Bärbel Rohrer**
  Professor
  Medical University of South Carolina

- **Abhigyan Satyam**
  Assistant Professor
  Harvard Medical School, Harvard University

- **Renfeng Guo**
  Chief Science Officer
  InflaRx N.V.

- **Ellen Cahir-McFarland**
  Senior Vice President, Research
  Annexon Biosciences

- **Karthik Viswanathan**
  Executive Director, Research
  Visterra, Inc.

- **Gerry Cox**
  Chief Medical Officer
  CANbridge Pharmaceuticals

- **Stephen Poor**
  Director External Opportunities & Translational Biomarkers
  Novartis Institutes for Biomedical Research

- **Petra Duda**
  Head of Development - Zilucoplan
  UCB

Proudly Sponsored By:

KYPHA  SVAO  ReAlta  Life Sciences  Quidel  Exsera BioLabs  National Jewish Health
Welcome to the 6th Complement-based Drug Development Summit

A plethora of novel complement approaches are set to progress through the clinic, but with many challenges still being faced, from maintaining drug safety to biomarker identification, it’s critical for the complement community to reunite and overcome these hurdles.

The highly anticipated 6th Complement-based Drug Development Summit returns as the only industry forum dedicated to maximizing the therapeutic and commercial opportunity of next-generation targeted complement approaches in the pan-disease setting.

Gathering industry heavyweights including Annexon, Apellis, Q32 Bio and more, this is your chance to evaluate preclinical and clinical pipeline progress, discover how dysregulated complement signaling contributes to disease and discuss the drug development strategies across diverse complement-mediated therapeutic opportunities.

Join forces with fellow industry pioneers this September to build meaningful partnerships and turbocharge complement-based therapies into the clinic and to patients in need.

Four Unmissable Highlights

Investigate the intricacies of complement signaling to identify novel drug targets with insights from University of Colorado, UCB and Medical University of South Carolina.

Analyze exclusive insights and learnings from clinical trials investigating complement inhibitors with insights from argenX, InflaRx and Novartis.

Explore the diversity of novel drug modalities in development to regulate the complement system with CANbridge Pharmaceuticals, Visterra and APTARION biotech.

Optimize therapeutic windows whilst maintaining drug safety and discuss strategic considerations for disease and geo expansion with Solid Biosciences and Zenas BioPharma.

What previous attendees have to say:

Great event that brought together important companies and people in complement and summarized the state of the art.

Brendan Kelly, Q32 Bio

It was great to hear about the current status of clinical-stage programs in the field, new and exciting preclinical research, and thought-provoking discussion from the audience!

Ron Gorham, Sanofi
Your Expert Speakers

- **Ellen Cahir-McFarland**
  Senior Vice President, Research
  **Annexon Biosciences**

- **Martin Kolev**
  Associate Director
  Complement Science
  **Apellis Pharmaceuticals**

- **Madhumita Das**
  Director, Immunology
  Discovery
  **Apellis Pharmaceuticals**

- **Axel Vater**
  Founder & Chief Scientific Officer
  **APTARION biotech AG**

- **Cynthia A. Lemere**
  Associate Professor of Neurology
  **Brigham & Women’s Hospital & Harvard Medical School**

- **Gerry Cox**
  Chief Medical Officer
  **CANBridge Pharmaceuticals**

- **Daniel E. Benjamin**
  Chief Executive Officer
  **Cascade Biotechnology Inc.**

- **Thomas J. Schall**
  President, Chief Executive Officer & Chairman of the Board
  **ChemoCentryx**

- **David Heja**
  Senior Scientist
  **eGenesis**

- **Edward F. Patz, Jr**
  CEO & James and Alice Chen Distinguished Professor of Radiology, Pharmacology & Cancer Biology
  **Grid Therapeutics, Duke University School of Medicine**

- **Abhigyan Satyam**
  Assistant Professor
  **Harvard Medical School, Harvard University**

- **Renfeng Guo**
  Chief Science Officer
  **InflaRx N.V.**

- **Martin J. Schmidt**
  Chief Scientific Officer
  **Kypha**

- **Ruchi Gupta**
  Director
  **Johnson & Johnson**

- **Stephen Poor**
  Director External Opportunities & Translational Biomarkers
  **Novartis Institutes for Biomedical Research**

- **Michelle Elvington**
  Scientific Director
  - Complement & Clinical Development
  **Kypha**

- **Bärbel Rohrer**
  Professor
  **Medical University of South Carolina**

---

**September 27-29 2022 | Boston, MA**
Your Expert Speakers

Michael Schwenkert  
Chief Technology Officer  
Svar

Jeffry B. Lawrence  
Interim Vice President, Clinical Development  
Solid Biosciences

Douangsone Vadysirisack  
Translational Biology Lead  
UCB

Petra Duda  
Head of Development - Zilucoplan  
UCB

Maciej Markiewski  
Professor  
Texas Tech University Health Sciences Center

Michael Wawersik  
Vice President of Research  
Q32 Bio Inc.

Ulrich Thienel  
Chief Executive Officer  
ReAlta Life Sciences

Michael Storek  
Head of Complement Cluster  
Sanofi

Karthik Viswanathan  
Executive Director, Research  
Visterra, Inc.

Keith Wilcoxen  
Senior Vice President, Global Research  
Zenas BioPharma

Nirmal K. Banda  
Professor  
University of Colorado Anschutz Medical Campus

Andrea Tenner  
Professor  
University of California, Irvine

Dorothy Schafer  
Associate Professor of Neurobiology  
UMass Chan Medical School

"Increased my baseline knowledge of current trends and challenges faced by our community"

Andrew Cassidy, Amryt Pharma

"It is great to join a body of people with a shared interest in complement"

Tim Higenbottam, Faculty of Pharmaceutical Medicine
Deep Dive into the Role of Complement in Neurological Disease Manifestation & Progression

Growing evidence has demonstrated a compelling role of the neuro-immune axis in CNS disease causality. This workshop will provide an opportunity to get to grips with the role of complement dysregulation in the CNS disease setting and to identify novel preclinical models and drug targets that can be pursued in the clinic.

This workshop will cover:

- Deciphering the role of complement dysregulation in manifestation and progression of neurological diseases
- Outlining preclinical models being used to study complement in the neurological setting
- Discussing disease-specific challenges of crossing the blood-brain barrier and complement activity in an immune-privileged space
- Identifying therapeutic opportunities for neurological disease patients

**Workshop Leaders**

Dorothy Schafer  
Associate Professor of Neurobiology  
UMass Chan Medical School

Cynthia A. Lemere  
Associate Professor of Neurology  
Brigham & Women’s Hospital & Harvard Medical School

Andrea Tenner  
Professor  
University of California, Irvine

---

Overall, a great informative conference that gives you a panoramic view on the progress being made in the complement space

Amol Karwa, Mallinckrodt Pharmaceuticals

Nice overview of the current complement landscape, relevant and insightful for my department’s efforts

Stephen Poor, Novartis
Conference Day One
Wednesday September 28, 2022

7.30 Registration & Morning Coffee

Michael Storek
Head of Complement Cluster
Sanofi

8.30 Chair’s Opening Remarks

State of Play of the Complement-Targeted Drug Development Field

8.40 Complement Industry Leaders’ Chat - 2021/22 in Review & Looking Ahead

This panel will discuss the key breakthroughs that have happened this year, the key challenges that have been overcome and where the biggest excitement remains:
• How do you perceive the complement drug development space? How has this changed in the past 12 months?
• What is missing from complement drug discovery and translation into the clinic?
• What are the gaps that both investors and drug developers must see, that we need to bring from other areas of biotech R&D?
• How are complement-targeted therapeutics going to compete against other drugs in the field?

Michael Storek
Head of Complement Cluster
Sanofi

Madhumita Das
Director, Immunology Discovery
Apellis Pharmaceuticals

Leveraging Innovation in Assay Development & Defining Therapeutic Windows of Drugs Across Complement Pathways to Elevate Drug Design

9.10 Overcoming Challenges for Accurate Real World Complement Analysis

Michelle Elvington
Scientific Director - Complement & Clinical Development
Kypha

• Review why complement analytes are unstable
• Current best practice for complement sample management is based on healthy normal donor samples – patient samples are different
• Understand how reliable testing is possible by tightly controlling or eliminating the clinical sample workflow from draw to analysis

Jeffry B. Lawrence
Interim Vice President, Clinical Development
Solid Biosciences

9.20 Complement Inhibitory Drugs: Dose Selection & Schedule for Different Indications Based Upon Disease Mechanism, Pharmacokinetics & Pharmacodynamics

• Assess how magnitude and clinical impact of complement activation in different diseases may differ significantly
• The optimal doses and schedules of administration of the same drug in different diseases may differ substantially
• Examine how the determination of optimal dosing in different diseases depends upon mechanism of complement activation and may be facilitated by pharmacokinetics and pharmacodynamics

Jeffry B. Lawrence
Interim Vice President, Clinical Development
Solid Biosciences

Ruchi Gupta
Director
Johnson & Johnson

9.50 Panel Discussion: Defining the Therapeutic Windows of Drugs to Ensure Patient Safety Whilst Maintaining Drug Efficacy

• Balancing the therapeutic index versus safety in targeting complement
• Discussing this in the context of disease versus healthy complement inhibition
• Reviewing the therapeutic window when you target classical, lectin or alternative pathways
• Discussing pharmacokinetics of targeting complement
• Specifying inclusion/exclusion criteria put in place specifically due to safety considerations e.g. avoiding comorbidities or infections

Michael Schwenkert
Chief Technology Officer
Svar

10.20 Importance of Complement Assays in Drug Development

• Complement is a necessary pathway to monitor in any drug development - not only when the pathway is directly targeted
• Discuss how functional and quantitative assays are equally important and will provide a more wholesome image of the situation
• Learn from Svar’s long experience with complement assays with special expertise in functional assay setups

10.30 Speed Networking Break

11.00 Morning Coffee Break
# Conference Day One
## Wednesday September 28, 2022

### Track A – Discovery & Preclinical Validation of Emerging Strategies
**Chair:** Nirmal K. Banda, Professor, School of Medicine, University of Colorado Anschutz Medical Campus

Revealing Complement Dysregulation in Disease to Identify Novel Therapeutic Targets

- **11.30 Therapeutic Targeting C5AR1 to Diagnosing & Preventing Early Rheumatoid Arthritis as a New Pathway to Precision Medicine**
  - Recently RNAi therapeutics using siRNAs are almost replacing antibody therapeutics
  - CRSAR1 gene is expressed high, correlated with disease activity score 28 and a valid therapeutic target in Early Rheumatoid Arthritis
  - Highlighting how single targeting of C5-C5AR1 axis is not sufficient but double targeting of C5 and C5AR1 expression with a new conjugate of anti-CSAR1-C5siRNA is effective in reducing arthritis
  - **Nirmal K. Banda, Professor, University of Colorado Anschutz Medical Campus**

- **12.00 Complement Inhibitor for the Treatment of Age-related Macular Degeneration: Target, Location of Delivery & Timing?**
  - Discover how the eye generates its own complement microenvironment, which is composed of RPE/choroid-derived proteins and those delivered by the liver (circulation), and set up in part by differential permeability of Bruch’s Membrane to complement proteins
  - Complement activation appears to occur outside of the Blood Retina Barrier (basal side of RPE, BrM and CC)
  - As the goal is to identify a treatment for dry AMD that can be used early in disease, to prevent conversion from early to intermediate AMD (i.e., in the presence of a presumably intact BRB), how do we deliver the therapeutics accordingly?
  - **Bärbel Rohrer, Professor, Medical University of South Carolina**

### Track B – Clinical Development & Commercialization Considerations
**Chair:** Michael Storek, Head of Complement Cluster, Sanofi

Clinical Update on Complement Therapeutics in the Clinic, Key Learnings & Future Directions

- **11.30 RLS-0071: Dual Target Inhibition in Support of Hypoxic Ischemic Encephalopathy**
  - RLS-0071 is a novel, dual-targeting peptide with upstream control of inflammatory pathways. Mutually supportive inhibition of complement and cellular inflammatory processes support lead candidate RLS-0071 development in hypoxic ischemic encephalopathy
  - Discussing the Phase 2 clinical trial in progress assessing safety, pharmacokinetics and pharmacodynamic biomarkers planned in HIE
  - Demonstrating a clean safety profile in Phase 1 human trial with encouraging target engagement data
  - **Ulrich Thienel, Chief Executive Officer, ReAlta Life Sciences**

- **11.40 A Phase 1 Study of CAN106: A Novel, Long-Acting, Anti-C5 Monoclonal Antibody in Development for Complement-Mediated Diseases**
  - Exploring data supporting anti-C5 mechanism of action
  - Sharing Phase 1 single ascending dose clinical trial data in healthy volunteers
  - Progressing into the clinic for paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases
  - **Gerry Cox, Chief Medical Officer, CANbridge Pharmaceuticals**

### 12.10 In Vitro Neuromuscular Junction Models to Functionally Dissect Anti-AChR Pathogenic Mechanism in Myasthenia Gravis

- Exploring three mechanisms of neurotransmission impairment by anti-acetylcholine receptor (AChR) autoantibodies in myasthenia gravis, including complement activation, antigenic modulation, and functional blockade
- In vitro NMJ (neuromuscular junction) models may offer an opportunity to dissect the contribution of pathogenic autoantibodies and may allow a tailored therapeutic strategy
- Sharing how Zilucoplan, an investigational macrocyclic peptide inhibitor of complement C5, prevented functional impairment induced by AChR+ myasthenia gravis patient sera in an in vitro neuromuscular junction model
- **Douangsone Vadysirisack, Translational Biology Lead, UCB**

- **12.10 Safety, Efficacy, Pharmacokinetics & Pharmacodynamics of ARGX-117, a Therapeutic Antibody Targeting Complement Factor 2**
  - Evaluating how the ARGX-117 antibody has been engineered to have a long half life
  - Demonstrating that administration of ARGX-117 in healthy volunteers is safe and well-tolerated
  - ARGX-117 is being studied in adults with multifocal motor neuropathy in a Phase 2 clinical study
  - **Emma Persson, Scientist, Clinical, argenx BV**

### 13.00 Lunch & Networking Break
14.00 Stop the Start: The Effect of Anti-C1q Inhibitors on Neurodegeneration

- C1q tags membranes for elimination via classical complement activation by microglia or macrophages
- Anti-C1q inhibitors provide synaptic and neuronal protection in multiple mouse models
- Annexon has developed fit-for-purpose C1q inhibitors for Ophthalmology and Neurodegeneration that have demonstrated proof of biology

Ellen Cahie-McFarland, Senior Vice President, Research, Annexon Biosciences

14.30 Targeted Inhibition of Intracellular Complement Activation to Control Tissue Injury

- Examining the role of intracellular complement activation in tissue damage
- Highlighting the development of in-vitro models to study complement activation
- Optimizing delivery of complement inhibitors to a target organ

Abhigyan Satyam, Assistant Professor, Harvard Medical School, Harvard University

15.00 Precision Antibody-Based Therapeutics for Complement Regulation

- Targeting critical components of the complement pathway can impact diseases that are initiated or exacerbated by complement dysregulation
- Antibody based therapeutics can be used to precisely target and potently inhibit complement activation
- Visterra has developed novel antibodies for targeting complement activation

Karthik Viswanathan, Executive Director, Research, Visterra, Inc.

14.00 Treatment of Critically Ill COVID-19 Patients with Vilobelimab, a First-in-Class Anti-C5a Antibody

- C5a/C5aR axis plays an essential role in COVID-19 pathogenesis
- C5a-induced neutrophil activation is a driving force in the development of severe COVID-19
- Understand how Vilobelimab treatment improves survival in critically ill COVID-19 patients

Renfeng Guo, Chief Science Officer, InflaRx N.V.

14.30 An Update & Analysis of the Macular Degeneration Complement Landscape

- Assessing the current status of complement therapeutics in clinical development
- What are the implications of month 24 Phase 3 data from APELLIS and Month 12 Phase 3 data from IVERIC for geographic atrophy treatment (intravitreal C3 and C5 therapy)?
- What is the potential of gene therapy and systemic approaches in clinical development vs intravitreal therapies for macular degeneration?

Stephen Poor, Director External Opportunities & Translational Biomarkers, Novartis Institutes for Biomedical Research

15.00 Phase 3 Data in Generalized Myasthenia Gravis

- Exploring complement involvement in myasthenia gravis pathophysiology
- Outlining the design and conduct of the zilucoplan Phase 3 study in gMG
- Evaluating phase 3 data of zilucoplan in gMG

Petra Duda, Head of Development – Zilucoplan, UCB

15.30 Afternoon Networking Break

Breakout Roundtable Discussions

16.30 Uncover the story behind leaps and setbacks from the movers and shakers of complement research and drug development. Each roundtable will be hosted by a complement R&D leader who will share a challenge, question or case study to discuss:

1. Complement Biomarkers, the Utility of Complement Assays & Evaluating the Best Methods to Accurately Quantify Complement Activation

   Martin J. Schmidt
   Chief Scientific Officer
   Kypha

2. Breaking Down Complement Pathways to Identify Which Complement Targets are Relevant to Particular Diseases & Why

   Speaker to Be Announced

17.00 Chair’s Closing Remarks

17.10 End of Conference Day One
Conference Day Two
Thursday September 29, 2022

8.00  Registration & Morning Coffee

Ruchi Gupta
Director
Johnson & Johnson

8.50  Chair’s Opening Remarks

Deciphering Key Learnings & Principals from Approval Journeys of Trailblazing Complement Drugs

Thomas J. Schall
President, Chief Executive Officer & Chairman of the Board
ChemoCentryx

9.00  Success Stories & Lessons Learned: TAVNEOS (Avacopan) – an Oral Inhibitor of the Complement C5a Receptor for the Treatment of ANCA-Associated Vasculitis

• Providing a disease and biology overview
• Sharing experiences from non-clinical and clinical development
• Addressing lessons learned from the journey

Exploring Complement Targets & Unique Complement Drug Development Considerations in the Cancer Setting

Martin Kolev
Associate Director
Complement Science
Apellis Pharmaceuticals

9.30  Inside-Out of Complement in Cancer Immunotherapy

• Examining why the role of complement in cancer is complex
• Investigating how the location of complement proteins expression and activation might determine its effect on tumorigenesis
• New anticancer therapeutic strategies need to take this complexity into account

Maciej Markiewski
Professor
Texas Tech University Health Sciences Center

10.00 Finding Optimal Targets for Complement-Based Cancer Therapy

• Despite strong preclinical evidence on a role of complement in promoting cancer, complement-based cancer therapies have not yet advanced to the clinic
• Recent pre- and clinical studies suggest that progression of several subsets of renal cell carcinoma can be driven by complement-mediated mechanisms, therefore, these subsets are potential targets for complement-based intervention
• Levels of complement fragments in plasma associate with the response to immune checkpoint inhibitors

10.30  Morning Refreshments & Networking Break

Madhumita Das
Director, Immunology Discovery
Apellis Pharmaceuticals

11.30  Expanding Horizons in Cancer Therapeutics Targeting the Complement Pathway

• Unravelling novel intricacies of complement cancer nexus will offer key insights
• Are mechanistic models authentic predictors of clinical scenario?
• Discussing why the selection of the right patient subsets for complement inhibition is the path forward

Edward F. Patz, Jr
CEO & James and Alice Chen Distinguished Professor of Radiology, Pharmacology & Cancer Biology
Grid Therapeutics, Duke University School of Medicine

12.00  Complement as a Natural Adjuvant to Promote Anti-Tumor Immunity in Cancer Therapy

• Exploring how the complement system interacts with the tumor microenvironment in driving anti-tumor immunity in cancer
• Human-derived antibodies can cause complement activation, tumor-specific cytotoxicity, and anti-tumor immunity
• Evaluating implications for metrics in measuring success of complement therapy in cancer, and subsequent novel trial design
### Conference Day Two
Thursday September 29, 2022

#### 12.30 Long-Term Graft Survival Achieved in NHP Recipients of Life-Sustaining, Endogenous Retrovirus-Free, Human-Compatible (HuCo™) Porcine Renal Xenografts

**David Heja**  
Senior Scientist  
eGenesis

- Understand how genome-wide inactivation of porcine retroviruses greatly reduces the risk of zoonosis in xenotransplantation
- Human immuneCompatibility of retrovirus-free porcine organ donors was enhanced using multiplex, precision genome editing to produce a safe source of human-compatible (HuCo™) porcine organ donors for human transplantation
- Demonstrating how human complement regulatory protein expressing HuCo™ donor kidneys show long-term survival in an NHP model of life-sustaining renal xenotransplantation

#### 13.00 Networking Lunch

#### 14.00 C5a Neutralization by Clinical-Stage AON-D21 Shows Promise in Animal Models from Pneumonia to Lung Cancer

**Axel Vater**  
Founder & Chief Scientific Officer  
APTARION biotech AG

- AON-D21 is a mirror-image (L-)RNA aptamer that binds C5a and inhibits its signaling on C5aR1 and C5aR2
- Analyze preclinical data showing that C5a-inhibition with AON-D21 is efficacious in diseases such as pneumonia, sepsis and lung cancer
- AON-D21 has passed Phase 1 First in Human studies and will enter a Phase 2 Proof of Concept trial shortly

#### Harnessing the Power of Locally Targeted Complement Inhibitors to Achieve Desired Therapeutic Safety & Efficacy Profiles

**Stefan Wawersik**  
Vice President of Research  
Q32 Bio Inc.

#### 14.30 Developing Locally Targeted Complement Therapeutics

- Reviewing strategies for locally targeted inhibitors
- Addressing pharmacology challenges of characterizing locally targeted drugs
- Discussing the advantages of local targeting - potency, durability, and safety

#### 15.00 Targeted Delivery Platform of sC3, a Complement Depleting Protein, Using Viral Delivery, Conjugate Guidance, & Localized Application Modalities

**Daniel E. Benjamin**  
Chief Executive Officer  
Cascade Biotechnology Inc.

- Discover how specific cell types in the retina and kidney can be targeted to express sC3
- Conjugate guidance and tissue specific local delivery are being developed to increase efficacy and decrease off target effects
- Taken together, these technologies allow Cascade to optimize treatment based on the therapeutic target

#### Discussing Market Access Strategies for Complement Targeted Therapies in Different Geos

**Keith Wilcoxen**  
Senior Vice President, Global Research  
Zenas BioPharma

#### 15.30 Opportunities for Complement Therapy in China

- Reflecting on the significant opportunities available for complement therapies in China
- Examining how the considerations for development in China differ from US/EU
- Outlining unique strategies that can be employed for approval of complement inhibitors in rare disease indications

#### 16.00 Chair’s Closing Remarks & End of Summit
We’ve entered a new era of complement-targeted drug development that is impossible to ignore. With the expansion into many other indications beyond rare diseases, the world of possibilities for complement-targeted drugs has opened greatly.

As the number of new drugs progressing into the clinic has skyrocketed, so has the necessity for partners, collaborators, and solution providers to support this expansion.

The 6th Complement-based Drug Development Summit is the only forum dedicated to complement-based drug development that brings together key leaders in this exciting space, including large pharma, biotech, academia, and technology providers. This unique, very timely and exclusive meeting will not be one to miss.

Use this opportunity to become part of the complement-based drug development community and showcase your expertise. If you provide services in biomarker identification, assay validation and development, preclinical models, clinical trial design, now’s the time to get in front of the key decision-makers of the field. Whether you need to communicate exciting progress, are looking to generate leads, or would like to understand what next generation investments the market wants, you can rely on our ability to advise and deliver the right solution for you.

Get in touch today to learn more about bespoke partnership opportunities.

**Attendance by Company Type**
- 20% Pharmaceutical
- 40% Biotech
- 40% Academia

**Attendance by Geo**
- 30% Europe
- 60% North America
- 10% Asia

*Expected attendance based on previous event

**GET INVOLVED**

Amy Wilson  
Partnerships Director  
Tel: +1 617 455 4188  
Email: sponsor@hansonwade.com

**Secure an exhibition booth to showcase your expertise and educate the industry on how you can support and streamline their efforts.**  
**Maximize the targeted networking opportunities to facilitate lead generation and build new relationships with senior level decision makers from leading pharma and biotech companies.**  
**Secure a branding or speaking opportunity to demonstrate your thought leadership, drive your brand exposure and differentiate yourself from competitors.**  
**Tailor your partnership package to meet your 2022 business objectives and educate key decision makers on how your expertise can help ensure complement-based therapeutics reach their full potential and reach patients in need.**
Our Partners

Hosting Partner

Kypha is delivering immune insights driven by the need for reliable and actionable immune activation results in any clinical setting. Kypha's complement activation diagnostics program focuses on reducing sample management requirements and removing preanalytical variability. As a result, Kypha's platforms are designed for low complexity protocols with disease specific multiplex testing panels and are currently deployed to clinical sites for validation and partner collaborations. Kypha was founded in 2010 with headquarters in St. Louis, MO, USA and Dublin, Ireland.

www.kypha.net

Innovation Partner

ReAlta Life Sciences’ EPICC peptides are based on the human astrovirus HAsTV-1, which causes a non-inflammatory, self-limiting gastroenteritis unique among viruses by inhibiting components of the innate immune system. ReAlta’s therapeutic peptides leverage these virus-derived mechanisms via small peptides to rebalance complement and inflammatory processes in the body. The company’s pipeline is led by RLS-0071, which has received Phase 2 IND clearance and Orphan Drug Designation by the FDA and EMA.

www.realtalifesciences.com

Innovation Partner

Svar means ‘answers’ in Swedish. We are a life science company with proud Scandinavian roots and values, and a global perspective. We focus on helping deliver the answers needed in drug discovery and clinical diagnostics, and the impact this has on human lives.

Svar is in a unique position to offer assistance in any complement therapeutic development project. We have robust platforms suited for all phases of drug development, as well as experience and knowledge from our diagnostic and bioanalytical services.

www.svarlifescience.com

Exhibition Partner

Quidel SPG is the option for all your research, biosafety and cytotoxicity testing needs. Quidel MicroVue products are a well-established name in immune system monitoring, assays for the assessment of Complement activation, as well as biochemical bone markers. Quidel offers products to meet biosafety testing and Complement dependent cytotoxicity testing needs, such as normal human sera, cobra venom factor, and Complement fragment assays. ELISA assays, depleted sera, proteins, monoclonal and polyclonal antibodies, antisera, antigens, controls, and special reagents are also available to round-out a comprehensive laboratory portfolio.

www.quidel.com/spg

Amy Wilson
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

GET INVOLVED

+1 617 455 4188  info@hansonwade.com
www.complement-therapeutics.com  Complement_US
Exhibition Partner

For 118 years, National Jewish Health has been at the forefront of research and medicine. We integrate the latest scientific discoveries with coordinated care for lung, heart and immune diseases. Our focus is to: Develop and provide innovative clinical programs for treating and rehabilitating patients of all ages and for preventing disease. Discover knowledge to enhance prevention, treatment and cures, through an integrated program of basic and clinical research. Educate scientists, physicians, health care professionals, and the public.

www.nationaljewish.org

Exhibition Partner

Exsera BioLabs brings unsurpassed expertise to the assessment of complement in adverse reactions to: immune complex, oligonucleotides, AAV, lipid nanoparticle or other inflammatory states. We balance that with an ability to accurately assess therapeutic inhibition of complement immunobiology. We excel in functional testing, activation measurements and multiplex analysis. Our Director is a recognized expert in the field having overseen countless studies and PI reports proving an unparalleled depth of knowledge and expertise. Combine that with a team with decades testing complement, Exsera BioLabs has the experience to understand your unique issues or complex results. Exsera is CAP/CLIA, FDA GLP & GCP compliant. Don’t know what you need from complement testing? We can also help with consultation and advising on your biomarker choice and study design.

www.exserabiolabs.org

An informative review of the current complement landscape and thoughts around complement development

Michael Simet, ReAlta Life Sciences, Inc.

Very good update as to the “state of the art” of complement-based drug development across therapeutic areas and applications

Jeffry Lawrence, Solid Biosciences

GET INVOLVED

Amy Wilson
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

www.complement-therapeutics.com
Complement_US
Secure Your Place Now

<table>
<thead>
<tr>
<th>Industry Pricing*</th>
<th>Register &amp; Pay By Friday, June 10</th>
<th>On the Door Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conference + Workshop</td>
<td>$2,498 (Save $1,150)</td>
<td>$3,648</td>
</tr>
<tr>
<td>Conference Only</td>
<td>$2,099 (Save $900)</td>
<td>$2,999</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Academic Pricing**</th>
<th>Register &amp; Pay By Friday, June 10</th>
<th>On the Door Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conference + Workshop</td>
<td>$1,998 (Save $1,150)</td>
<td>$3,148</td>
</tr>
<tr>
<td>Conference Only</td>
<td>$1,699 (Save $900)</td>
<td>$2,599</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Service Provider Pricing</th>
<th>Register &amp; Pay By Friday, June 10</th>
<th>On the Door Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conference + Workshop</td>
<td>$3,198 (Save $1,150)</td>
<td>$4,348</td>
</tr>
<tr>
<td>Conference Only</td>
<td>$2,699 (Save $900)</td>
<td>$3,599</td>
</tr>
</tbody>
</table>

*You must currently be developing drug candidates publicly (evidence on company website required).
**Reduced rates are available for full-time academics, please get in touch at info@hansonwade.com for more information.

Team Discounts*
- 10% discount – 3 Delegates
- 15% discount – 4 Delegates
- 20% discount – 5+ Delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time. Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.
Contact: register@hansonwade.com